Table 3

Summary of serum IgA and IgG responses, by dose

ResponseGMT, EU/ml (95% CI)a
5 μg (n = 5 subjects)b25 μg (n = 6 subjects)50 μg (n = 12 subjects)100 μg (n = 12 subjects)
Anti-dmLT serum IgA
    Baseline124 (25, 620)130 (77, 219)211 (119, 373)311 (185, 525)
    Day 8167 (28, 994)264 (46, 1,527)822 (358, 1,885)591 (233, 1,501)
    Day 14177 (32, 977)263 (51, 1,350)1,490 (497, 4,464)675 (280, 1,631)
    Day 28164 (33, 827)328 (109, 990)1,030 (368, 2,882)800 (412, 1,553)
    Total no. of responders (%)c0/5 (20)1/6 (16.7)8/12 (66.7)4/12 (33.3)
Anti-dmLT serum IgG
    Baseline369 (158, 864)424 (107, 1,675)573 (250, 1,315)514 (286, 924)
    Day 8487 (136, 1,744)627 (89, 4,414)1,872 (526, 6,655)1,063 (359, 3,148)
    Day 14615 (111, 3,404)756 (93, 6,138)3,494 (776, 15,723)1,215 (352, 4,190)
    Day 28583 (117, 2,913)853 (111, 6,536)3,120 (697, 13,977)1,739 (574, 5,272)
    Total no. of responders (%)c1/5 (20)1/6 (16.7)7/12 (58.3)4/12 (33.3)
  • a Values are GMT (95% CI) unless otherwise stated.

  • b A nonassociated death occurred prior to the collection of the day 8 specimen.

  • c A 4-fold increase in antibody over baseline, at any time postvaccination.